Company: LNAI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001731122-25-000765
Chunk: 145

Company: Lunai Bioworks Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 145
---
-Weinberg equilibrium p-values, and linkage disequilibrium.

Other post-processing steps may
include genotype calling, population stratification and association analysis. Specific post-processing steps may vary depending on the
type of array used, the study design, and the analytical goals.

Planning for Commercialization

Partnerships in Development

To enhance multi-omic and multi-modal
capacity, and to work to validate those capabilities with human samples including liquid-biopsy-based tests/test kits, Renovaro Cube is
actively pursuing relationships with leading academic cancer centers, pathology and imagery centers in Europe, the USA and the Middle
East. In certain cases, scopes of work are in process. This is a very attractive model for partners to be involved with Renovaro Cube
to perform multi-omics genetic analysis using liquid biopsies.

30

Resources

Renovaro Cube intends to hire additional
staff to increase the speed and velocity of its organization, including the development of the AI platform and the opportunities to deploy
the AI platform for research perspective and ultimately for clinical practice and into clinical trials.

In addition, Renovaro Cube intends
to build out its infrastructure by leasing space for storage, networking and hosting facilities.

Target Market

Renovaro Cube’s intended
customers will be hospitals, clinics, insurance companies, pharmaceutical companies, biotech companies, research centers, physicians and
individual patients.

Renovaro Cube aims to utilize its
AI technology to commercialize products and test kits for healthcare providers, hospitals, clinics and doctors that will expedite diagnosis
and the selection of appropriate treatment for various types of cancer. Renovaro Cube intends to differentiate its products based on the
following factors:

    ●
    Proprietary and unique panel mining algorithms to create multiple biomarker stratifications per cancer;

    ●
    Explainable AI, offering traceability between the prediction and the exact biomarkers, panels and genes;

    ●
    Differential diagnosis, inclusion and exclusion of cancer types based on facts; and

    ●
    Precision diagnosis, with a high accuracy percentage with machine-learning tuning.

The multi-omic design of Renovaro
Cube’s AI platform enables the use of different molecular layers, such as epigenomics, transcriptomics, and metabolomics, together
with genomics and clinical data.

Panel Mining 

The unique panel mining technique
in Renovaro Cube’s technology repeatedly investigates genes to identify relevant biomarkers. The proprietary technique in Renovaro
Cube’s technology not only searches for individual biomarkers